KR20010101603A - 이미다조[1,5-ａ]-피리도[3,2-ｅ]-피라지논의 약제로서의용도 - Google Patents

이미다조[1,5-ａ]-피리도[3,2-ｅ]-피라지논의 약제로서의용도 Download PDF

Info

Publication number
KR20010101603A
KR20010101603A KR1020017009112A KR20017009112A KR20010101603A KR 20010101603 A KR20010101603 A KR 20010101603A KR 1020017009112 A KR1020017009112 A KR 1020017009112A KR 20017009112 A KR20017009112 A KR 20017009112A KR 20010101603 A KR20010101603 A KR 20010101603A
Authority
KR
South Korea
Prior art keywords
alkyl
formula
aryl
compound
pyrido
Prior art date
Application number
KR1020017009112A
Other languages
English (en)
Korean (ko)
Inventor
회프겐노르베르트
슈첼레니슈테판
데겐하르트마르크스
에게를란트우테
Original Assignee
노왈드
아르쯔나이미텔베르크 드레스덴 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999102082 external-priority patent/DE19902082A1/de
Priority claimed from DE1999161302 external-priority patent/DE19961302A1/de
Application filed by 노왈드, 아르쯔나이미텔베르크 드레스덴 게엠베하 filed Critical 노왈드
Publication of KR20010101603A publication Critical patent/KR20010101603A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020017009112A 1999-01-20 2000-01-14 이미다조[1,5-ａ]-피리도[3,2-ｅ]-피라지논의 약제로서의용도 KR20010101603A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE1999102082 DE19902082A1 (de) 1999-01-20 1999-01-20 Verwendung von Imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erectiler Dysfunktion und Verfahren zu deren Herstellung
DE19902082.5 1999-01-20
DE19961302.8 1999-12-18
DE1999161302 DE19961302A1 (de) 1999-12-18 1999-12-18 Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
PCT/EP2000/000260 WO2000043392A2 (de) 1999-01-20 2000-01-14 Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel

Publications (1)

Publication Number Publication Date
KR20010101603A true KR20010101603A (ko) 2001-11-14

Family

ID=26051406

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017009112A KR20010101603A (ko) 1999-01-20 2000-01-14 이미다조[1,5-ａ]-피리도[3,2-ｅ]-피라지논의 약제로서의용도

Country Status (23)

Country Link
EP (1) EP1144410A2 (sk)
JP (1) JP2002535330A (sk)
KR (1) KR20010101603A (sk)
CN (1) CN1344268A (sk)
AR (1) AR022318A1 (sk)
AU (1) AU2291200A (sk)
BG (1) BG105714A (sk)
BR (1) BR0007613A (sk)
CA (1) CA2296224A1 (sk)
CO (1) CO5190700A1 (sk)
CZ (1) CZ20012627A3 (sk)
EA (1) EA200100792A1 (sk)
EE (1) EE200100377A (sk)
HU (1) HUP0105132A3 (sk)
ID (1) ID29790A (sk)
IL (1) IL144156A0 (sk)
IS (1) IS5987A (sk)
LT (1) LT2001078A (sk)
LV (1) LV12793B (sk)
NO (1) NO20013334D0 (sk)
SK (1) SK10322001A3 (sk)
TR (1) TR200102121T2 (sk)
WO (1) WO2000043392A2 (sk)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
JP2005513060A (ja) * 2001-12-17 2005-05-12 アルタナ　ファルマ　アクチエンゲゼルシャフト 選択的ｐｄｅ５阻害剤の新規使用
US6916345B2 (en) 2002-02-12 2005-07-12 L'oreal S.A. 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres
FR2835741B1 (fr) * 2002-02-12 2006-05-05 Oreal Nouveaux coupleurs 6-alcoxy-2,3-diaminopyridine utiles pour la teinture des fibres keratiniques
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
EP1786428B1 (en) * 2004-08-17 2012-05-16 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
ES2536906T3 (es) 2006-12-13 2015-05-29 Aska Pharmaceutical Co., Ltd. Derivado de quinoxalina
WO2009070583A1 (en) * 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
KR20100110804A (ko) 2007-11-30 2010-10-13 와이어쓰 엘엘씨 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진
US9643970B2 (en) 2011-10-10 2017-05-09 H. Lundbeck A/S Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
JP5842640B2 (ja) * 2012-01-31 2016-01-13 株式会社東洋新薬 ホスホジエステラーゼ３阻害剤
WO2016022825A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
WO2016022836A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
PT3865484T (pt) 2015-07-07 2024-01-30 H Lundbeck As Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
EP1144410A2 (de) 2001-10-17
AR022318A1 (es) 2002-09-04
IS5987A (is) 2001-06-29
IL144156A0 (en) 2002-05-23
BR0007613A (pt) 2001-10-30
CO5190700A1 (es) 2002-08-29
EA200100792A1 (ru) 2002-10-31
HUP0105132A3 (en) 2002-12-28
LV12793A (lv) 2002-02-20
NO20013334L (no) 2001-07-05
AU2291200A (en) 2000-08-07
HUP0105132A2 (hu) 2002-05-29
ID29790A (id) 2001-10-11
EE200100377A (et) 2002-10-15
NO20013334D0 (no) 2001-07-05
LV12793B (lv) 2002-05-20
BG105714A (en) 2002-02-28
WO2000043392A2 (de) 2000-07-27
CZ20012627A3 (cs) 2002-01-16
CN1344268A (zh) 2002-04-10
SK10322001A3 (sk) 2002-07-02
WO2000043392A3 (de) 2000-09-28
LT2001078A (en) 2002-08-26
TR200102121T2 (tr) 2002-01-21
JP2002535330A (ja) 2002-10-22
CA2296224A1 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
KR20010101603A (ko) 이미다조[1,5-ａ]-피리도[3,2-ｅ]-피라지논의 약제로서의용도
US6462047B1 (en) Carboline derivatives as cGMP phosphodiesterase inhibitors
CA2340636C (en) Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents
US6143757A (en) Chemical compounds
SK13232002A3 (sk) Použitie pyrido[3,2-e]-pyrazinónov ako inhibítorov fosfodiesterázy 5 na liečbu erektilnej dysfunkcie
SK284039B6 (sk) Liečivo na znižovanie hladiny lipidov, hladiny triglyceridov alebo hladiny cholesterolu
WO2003097064A1 (fr) Agent de traitement du diabète
CS153392A3 (en) Azole derivatives, process of their preparation and a pharmaceuticalcomposition containing said derivatives
KR101233828B1 (ko) 문맥성 고혈압의 예방 및/또는 치료
JPH01299231A (ja) 循環器系疾患治療薬
EP0682947B1 (en) Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia
JP4217605B2 (ja) ピラジノ［１’，２’：１，６］ピリド［３，４−ｂ］インドール−１，４−ジオン誘導体
JP2005524695A (ja) 呼吸機能不全を治療するためのグアニル酸シクラーゼ活性化剤の新規の使用
AU735980B2 (en) A method of treating liver disease and like indications with vasodilating agents
US6465465B1 (en) Process for the treatment of erectile dysfunction and product therefor
JP4339679B2 (ja) Ｐｄｅ５阻害剤としてのカルボリン誘導体
JP2997894B2 (ja) 循環器系疾患の予防及び治療剤
TW526200B (en) Sulfonamide-substituted compounds, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
MXPA01007380A (en) Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments
US4439442A (en) Naftidrofuryl citrate and therapeutic applications
US20140330022A1 (en) Collateral blood circulation development promoter
ZA200105719B (en) Use of imidazo[1,5-A]-pyrido[3,2-E]-pyrazinones as medicaments.
JPH07110860B2 (ja) １−（イミダゾ〔１，２−ａ〕ピリジン−６−イル）−２−プロパノン誘導体
DE19961302A1 (de) Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
CN117924280A (zh) 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid